Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 27;15(9):472. doi: 10.1186/s13059-014-0472-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Li et al.; licensee BioMed Central Ltd. 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Loci with and without significant epiallele shift. Epiallele pattern proportion change on non-eloci (a, Δ = 0, chr1: 234367244-234367265, SLC35F3 exon), non-eloci (b, Δ = -20, chr1: 103319658-103319682, downstream of COL11A1 gene), drift eloci (c, model II, Δ = -80, chr16: 330195-330217, epipolymorphism at diagnosis: 0.27, at relapse: 0.62, increased by 0. 35, ARHGDIG promoter) and selection eloci (d, model I, Δ = -114 , epipolymorphism at diagnosis:0.68, at relapse: 0.15, decreased by 0. 53, chr10: 109674359- 109674402, SORCS1 distal upstream). Model I is defined as eloci with increased epigenetic tumor heterogeneity measured by epipolymorphism. Model II is defined as eloci with decreased epigenetic tumor heterogeneity measured by epipolymorphism.

Inline graphic — Loci with and without significant epiallele shift. Epiallele pattern proportion change on non-eloci (a, Δ = 0, chr1: 234367244-234367265, SLC35F3 exon), non-eloci (b, Δ = -20, chr1: 103319658-103319682, downstream of COL11A1 gene), drift eloci (c, model II, Δ = -80, chr16: 330195-330217, epipolymorphism at diagnosis: 0.27, at relapse: 0.62, increased by 0. 35, ARHGDIG promoter) and selection eloci (d, model I, Δ = -114 , epipolymorphism at diagnosis:0.68, at relapse: 0.15, decreased by 0. 53, chr10: 109674359- 109674402, SORCS1 distal upstream). Model I is defined as eloci with increased epigenetic tumor heterogeneity measured by epipolymorphism. Model II is defined as eloci with decreased epigenetic tumor heterogeneity measured by epipolymorphism.